Work

Figures S1-S7 from CYR61/CCN1 Regulates dCK and CTGF and Causes Gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma

Year: 2023

Type: other

Abstract: Fig. S1. Detection of cross-reactivity of Cyr61 and CTGF antibodies; Fig. S2. CYR61 ablation in AsPC-1 Cell Line using CRISPR/Cas9 Gene Editing; Fig. S3. Knockdown of CYR61 in Panc-1 cells and AsPC-1 cells using stable transfection of shRNA and CRISPR/Cas9 Gene Editing techniques, respectively; Fig. S4. CYR61 status in sub-populations (SP and NSP) in Panc-1 cells; Fig. S5. CYR61 suppresses the effect of Gemcitabine (GEM) on sphere-forming ability of Panc-1 cells; Fig. S6. Time-dependent effect of gemcitabine (GEM) on cell viability of three different PDAC cell lines; Fig. S7. Effect of hrCYR61/CCN1 on ð�›,-SMA expression in HPaSteC cells

DOI: 10.1158/1535-7163.22505772

Authors: Gargi Maity, Arnab Ghosh, Vijayalaxmi Gupta, Inamul Haque, Sandipto Sarkar, Amlan Das, Kakali Dhar, Sneha Bhavanasi, Sumedha S. Gunewardena, Daniel D. Von Hoff, Sanku Mallik, Suman Kambhampati, Sushanta K. Banerjee, Snigdha Banerjee

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362610018

Cites:

Cited by:

Related to: 10